Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review

Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review BioDrugs (2017) 31:299–316 DOI 10.1007/s40259-017-0231-8 SYSTEMATIC REVIEW Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review 1 2 3 4 • • • • Vibeke Strand Alejandro Balsa Jamal Al-Saleh Leonor Barile-Fabris 5 6 7 8 • • • • Takahiko Horiuchi Tsutomu Takeuchi Sadiq Lula Charles Hawes 8 9 Blerina Kola Lisa Marshall Published online: 13 June 2017 The Author(s) 2017. This article is an open access publication Abstract (AS), non-radiographic axial spondyloarthritis (nr-axSpA), Objectives A systematic review was conducted to explore psoriasis (Ps), Crohn’s disease, and ulcerative colitis. the immunogenicity of biologic agents across inflammatory Results Of [21,000 screened publications, 443 were diseases and its potential impact on efficacy/safety. included. Anti-drug antibody (ADAb) rates varied widely Methods Literature searches were conducted through among biologics across diseases (and are not directly November 2016 to identify controlled and observational comparable because of immunoassay heterogeneity); the studies of biologics/biosimilars administered for treatment highest overall rates were reported with infliximab of rheumatoid arthritis (RA), psoriatic arthritis (PsA), (0–83%), adalimumab (0–54%), and infliximab biosimilar juvenile idiopathic arthritis (JIA), ankylosing spondylitis CT-P13 (21–52%), and the lowest with secukinumab (0–1%), ustekinumab (1–11%), etanercept (0–13%), and golimumab (0–19%). Most ADAbs were neutralizing, Electronic supplementary http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png BioDrugs Springer Journals

Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review

Loading next page...
 
/lp/springer_journal/immunogenicity-of-biologics-in-chronic-inflammatory-diseases-a-tdoo0icJUx
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by The Author(s)
Subject
Biomedicine; Molecular Medicine; Antibodies; Cancer Research; Pharmacotherapy
ISSN
1173-8804
eISSN
1179-190X
D.O.I.
10.1007/s40259-017-0231-8
Publisher site
See Article on Publisher Site

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial